49 Baillie Gifford Alnylam Pharmaceuticals Trades
Baillie Gifford's position in Alnylam Pharmaceuticals is currently worth $1.38B. That's 0.99% of their equity portfolio (24th largest holding). The investor owns 2.35% of the outstanding Alnylam Pharmaceuticals stock. The first Alnylam Pharmaceuticals trade was made in Q1 2013. Since then Baillie Gifford bought shares 25 more times and sold shares on 23 occasions. The stake costed the investor $284M, netting the investor a gain of 384% so far.
Avg closing price
Price range
Sold 17.1% shares (-626k shares)
Q2 2025
Avg closing price
$276.90
Price range
$224.32
-
$326.09
Sold 9.5% shares (-383k shares)
Q1 2025
Avg closing price
$256.56
Price range
$233.07
-
$290.70
Sold 17.3% shares (-847k shares)
Q4 2024
Avg closing price
$262.40
Price range
$232.27
-
$300.55
Sold 19.0% shares (-1.15M shares)
Q3 2024
Avg closing price
$260.22
Price range
$233.81
-
$287.01
Sold 8.9% shares (-591k shares)
Q2 2024
Avg closing price
$157.87
Price range
$143.31
-
$247.00
Sold 4.9% shares (-344k shares)
Q1 2024
Avg closing price
$166.82
Price range
$146.51
-
$198.20
Sold 14.7% shares (-1.2M shares)
Q4 2023
Avg closing price
$170.34
Price range
$151.41
-
$196.57
Sold 2.7% shares (-229k shares)
Q3 2023
Avg closing price
$190.79
Price range
$170.77
-
$211.65
Sold 2.9% shares (-247k shares)
Q2 2023
Avg closing price
$198.26
Price range
$185.01
-
$212.05
Sold 8.2% shares (-769k shares)
Q1 2023
Avg closing price
$210.20
Price range
$182.66
-
$235.53
Sold 1.1% shares (-107k shares)
Q4 2022
Avg closing price
$213.29
Price range
$185.11
-
$241.31
Sold 4.6% shares (-454k shares)
Q3 2022
Avg closing price
$190.40
Price range
$138.54
-
$233.85
Sold 1.7% shares (-171k shares)
Q2 2022
Avg closing price
$141.87
Price range
$120.42
-
$169.29
Sold 4.5% shares (-477k shares)
Q1 2022
Avg closing price
$152.35
Price range
$127.18
-
$173.91
Increased shares by 1.9% (+201k shares)
Q4 2021
Avg closing price
$185.86
Price range
$159.56
-
$209.29
Increased shares by 1.9% (+191k shares)
Q3 2021
Avg closing price
$187.58
Price range
$169.75
-
$207.73
Increased shares by 1.5% (+150k shares)
Q2 2021
Avg closing price
$146.46
Price range
$128.63
-
$176.89
Increased shares by 10.3% (+943k shares)
Q1 2021
Avg closing price
$150.49
Price range
$126.83
-
$175.69
Increased shares by 2.7% (+241k shares)
Q4 2020
Avg closing price
$133.53
Price range
$122.97
-
$147.00
Increased shares by 2.8% (+243k shares)
Q3 2020
Avg closing price
$142.11
Price range
$121.19
-
$165.49
News about Alnylam Pharmaceuticals Inc and Baillie Gifford
Baillie Gifford Adjusts Stake in Alnylam Pharmaceuticals
Baillie Gifford Adjusts Stake in Alnylam Pharmaceuticals